| 2026-08-05 | Transcript | Q2 FY26 earnings call transcript |
| 2026-08-05 | Press release | Zevra Reports Second Quarter 2026 Financial Results and Corporate Update |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-04 | Press release | Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference |
| 2026-08-03 | Press release | Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) |
| 2026-07-24 | Press release | Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union |
| 2026-07-22 | Press release | Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call |
| 2026-06-23 | Press release | Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) |
| 2026-06-11 | Press release | Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition |
| 2026-06-08 | Press release | Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA |
| 2026-06-05 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-29 | Press release | Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-12 | Press release | Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference |
| 2026-05-06 | Press release | Zevra Reports First Quarter 2026 Financial Results and Corporate Update |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-22 | Press release | Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call |
| 2026-04-20 | Proxy | Definitive proxy statement |
| 2026-03-20 | Press release | Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-16 | Press release | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million Companies Resolve Lawsuit in Delaware |
| 2026-03-16 | 8-K | Form 8-K, Item 1.01 |
| 2026-03-10 | Transcript | Q4 FY25 earnings call transcript |
| 2026-03-09 | Press release | Zevra Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-09 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-09 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-05 | Press release | Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer |
| 2026-03-02 | Press release | Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call |
| 2026-02-25 | Press release | Zevra Therapeutics to Present at the Citizens Life Sciences Conference |
| 2026-02-04 | Press release | Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ |
| 2026-02-02 | Press release | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 |
| 2026-01-26 | Press release | Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ |
| 2026-01-08 | Press release | Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference |
| 2025-12-17 | 8-K | Form 8-K, Item 5.02 |
| 2025-12-02 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-20 | 8-K | Form 8-K, Item 5.02 |
| 2025-11-05 | Press release | Zevra Reports Third Quarter 2025 Financial Results and Corporate Update |
| 2025-11-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-05 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-27 | Press release | Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call |